Prostate_cancer_Takeda

Takeda Pharmaceutical Company has unblinded ELM-PC 5 Phase III study of non-steroidal, selective inhibitor of 17,20-lyase, Orteronel, in patients with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed post-chemotherapy based on interim analysis.

Pre-specified interim analysis, which was conducted by the Independent Data Monitoring Committee (IDMC), indicated that the study would not meet the primary endpoint of improved overall survival.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Designed to assess orteronel plus prednisone compared with placebo plus prednisone, the study’s interim analysis failed to show an advantage for orteronel plus prednisone for the secondary endpoint, radiographic progression-free survival (rPFS) over the control arm.

Takeda oncology therapeutic area unit global head Dr Michael Vasconcelles said the ELM-PC 5 study failed to meet the primary endpoint of improved overall survival, but the company remains committed to developing new therapies for patients with prostate cancer.

"We would like to acknowledge with gratitude the patients, their families, and the study investigators for their significant contributions to the ELM-PC 5 trial."

"We would like to acknowledge with gratitude the patients, their families, and the study investigators for their significant contributions to the ELM-PC 5 trial," Vasconcelles said.

See Also:

All ELM-PC 5 study patients randomised to orteronel will continue on therapy following consultation with their physicians and study investigators.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The appropriate health authorities and clinical study investigators are being notified of unblinding of ELM-PC 5 Phase III study.

Ongoing, Takeda-sponsored trials with orteronel, including the ELM-PC 4 pivotal Phase III study (C21004) comparing orteronel plus prednisone to placebo plus prednisone in mCRPC patients new to chemotherapy.

Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer, Gleason pattern 4. H&E stain. Photo: courtesy of Nephron.